Genetically engineered biological therapy of severe bronchial asthma with benralizumab


DOI: https://dx.doi.org/10.18565/pharmateca.2025.6.55-60

Trushina E.Yu., Kostina E.M., Tipikin V.A., Illarinov I.I., Orlova E.A., Turovskaya A.A.

1) Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Penza, Russia; 2) Tambov State University named after G.R. Derzhavin, Tambov, Russia
Genetically engineered biological therapy (GEBT) of bronchial asthma (BA) is a modern method of treating severe forms of the disease that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, six monoclonal antibody drugs for the treatment of severe bronchial asthma (anti-IgE – omalizumab), interleukin (IL)-5 antagonists (anti-IL-5 – mepolizumab, reslizumab) and its receptor (anti-IL-5Rα – benralizumab), as well as antibodies that selectively bind to the IL-4 and IL-13 receptor (anti-IL-4/13Rα - dupilumab) and tezepelumab, promoting the inhibition of thymic stromal lymphopoietin (TSLP) are registered in Russia.
A special group consists of patients with the eosinophilic phenotype of BA, characterized by a severe uncontrolled course and resistance to standard treatment regimens in accordance with the basic step therapy of the disease.
The article presents a clinical case of the effectiveness of GEBT using benralizumab as an example in a patient with severe uncontrolled bronchial asthma (eosinophilic phenotype).
Keywords: eosinophilic phenotype, eosinophilia, severe bronchial asthma, targeted therapy
Read entire article

About the Autors

Elena Yu. Trushina, Cand. Sci. (Med.), Associate Professor, Department of Pulmonology and Phthisiology, Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education (Penza), Associate Professor, Department of Hospital Therapy with a Course in Psychiatry, Institute of Medicine and Health Protection, Tambov State University named after G.R. Derzhavin, Tambov, Russia; trushina.lena@mail.ru; ORCID: https://orcid.org/0000-0001-5673-9195, eLibrarySPIN: 2164-6580 (corresponding author)
Elena M. Kostina, Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Penza, Russia; ORCID: https://orcid.org/000-0003-1797-8040
Valery A. Tipikin, Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Penza, Russia; ORCID: https://orcid.org/0009-0000-0990-4661
Ilya I. Illarionov, Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Penza, Russia; ORCID: https://orcid.org/0009-0008-0725-3242
Ekaterina A. Orlova, Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Penza, Russia; ORCID: https://orcid.org/0000-0003-1402-2940
Alina A. Turovskaya, Penza Institute for Advanced Medical Training – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Penza, Russia; ORCID: https://orcid.org/0000-0002-5138-808X


Similar Articles

Back to Content

Бионика Медиа